Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Gastrointestinal 1

Conditions

Smoldering Multiple Myeloma 3Pancreatic Neoplasms 2Multiple Myeloma 2Melanoma 2Triple Negative Breast Neoplasms 1PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Multiple Endocrine Neoplasia 1Lung Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Breast Diseases 1Arthritis, Rheumatoid 1Acute Graft Versus Host Disease 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × Leflunomide × Clear all
NCT06229340 2024-01-29

NТО-RAS

N.N. Petrov National Medical Research Center of Oncology

Phase 2 Recruiting
20 enrolled
DermatologicGastrointestinalThoracic

Lung Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01611675 2017-04-06

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Massachusetts General Hospital

Phase 1 Terminated
3 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡